Experienced in Hypercalcemia

Pieter C. Sonneveld

Erasmus MC
Rotterdam, ZH, NL 
Experienced in Hypercalcemia
Erasmus MC
Rotterdam, ZH, NL 
OverviewLocationsClinical Research

Overview

Pieter Sonneveld practices in Rotterdam, Netherlands. Mr. Sonneveld is rated as an Experienced expert by MediFind in the treatment of Hypercalcemia. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Primary Amyloidosis, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 357 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hypercalcemia.

Gender
Male

Locations

Erasmus MC
Rotterdam, ZH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy
A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy
Enrollment Status: Active_not_recruiting
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drugs: Daratumumab, Velcade, Lenalidomide, Dexamethasone
Study Phase: Phase 3
An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma
An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: October 23, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

357 Total Publications

The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.
The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.
Journal: Haematologica
Published: July 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sonneveld's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile